Deborah Heart and Lung Center Introduces the Ivenix Infusion System to the Hospital

Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system.

“Though everyone is familiar with IV pump delivery systems used to administer medications during a patient’s hospital stay, improvements in technology have allowed us to do it in a controlled and measured way,” said Rita Zenna, RN, Deborah’s Vice President for Patient Care Services. “This is why we replaced our existing pumps with Ivenix, a state-of-the-art infusion system capable of measuring and controlling medication delivery.”

“Our staff is thrilled with how easy the new pumps are to work with and the enhanced capabilities that are offered,” added Sue Campano, Deborah’s Vice President for Support Services. “Our nurses collaborated extensively when evaluating our choices and ultimately selected Ivenix, a solution they believed would best meet their ability to care for patients.”

“We are enthusiastic about the opportunity to partner with Deborah Heart and Lung Center and bring this innovative infusion system to more clinicians and patients,” said Susan Niemeier, Chief Nursing Officer of Ivenix. “Advancing medication safety and clinical outcomes is critical for a hospital, and we’re honored to support the Deborah Heart’s efforts to protect patient health.”

The Ivenix Infusion System includes a large-volume infusion pump, portfolio of administration sets, and infusion management software with unique capabilities new to the infusion therapy market. Its adaptive fluid delivery reduces flow and accuracy variability to help improve patient safety. Its patient-centered design benefits patients because clinicians spend less time troubleshooting pumps or resolving nuisance alarms, which simplifies infusion delivery for those providing bedside care. Additionally, the Ivenix System can seamlessly integrate with Deborah Heart’s electronic medical record and other hospital information systems, further reducing the possibility of patient medication errors.

“We are excited about how the system is designed to prevent medication errors, reduce nuisance alarms and other common interruptions,” said Zenna. “This will have a significant impact on our ability to provide high-quality care and ensure our patients get the rest needed after surgery.” She added, “We continue to invest in smart technology, and this was a natural next step for us. Our clinical teams are pleased with how smoothly the system was rolled out across the entire hospital.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”